Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21130356 | 0.94 | LMNA (0.41) | LMNAKDM4EPOLBPDE2APGK1 | |
| SCHEMBL21130358 | 0.84 | LMNA (0.49) | LMNAKDM4EPOLBPGK1ELANE | |
| SCHEMBL19914274 | 0.82 | SMN1; SMN2 (0.42) | LMNAKDM4EPOLBPDE2APGK1 | |
| SCHEMBL21130355 | 0.81 | LMNA (0.52) | LMNAKDM4EPOLBPGK1ELANE | |
| SCHEMBL21130278 | 0.81 | LMNA (0.49) | LMNAKDM4EPOLBELANE | |
| SCHEMBL21066420 | 0.79 | IDO1 (0.34) | PDE2APGK1IDO1EPHX2 | |
| SCHEMBL19914310 | 0.79 | PGK1 (0.38) | KDM4EPDE2APGK1IDO1EPHX2 | |
| SCHEMBL21130282 | 0.78 | LMNA (0.44) | LMNAKDM4EPOLBPDE2AELANE | |
| SCHEMBL19914283 | 0.78 | CHRNB2 (0.40) | LMNAPOLBPDE2APGK1IDO1 | |
| SCHEMBL17087996 | 0.76 | LMNA (0.46) | LMNAKDM4EPOLBELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | B3GNT2, RPN2, RPN1 | LMNA 1548/4885KDM4E 3731/4885POLB 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.